1. Home
  2. CVKD vs HCTI Comparison

CVKD vs HCTI Comparison

Compare CVKD & HCTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

N/A

Current Price

$1.71

Market Cap

3.4M

Sector

Health Care

ML Signal

N/A

HCTI

Healthcare Triangle Inc.

N/A

Current Price

$2.95

Market Cap

3.0M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
CVKD
HCTI
Founded
2022
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
3.4M
3.0M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
CVKD
HCTI
Price
$1.71
$2.95
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $14.00
N/A
AVG Volume (30 Days)
★ 103.3K
96.9K
Earning Date
11-16-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 23.94
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $13,891,000.00
Revenue This Year
N/A
$179.58
Revenue Next Year
N/A
$4.39
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 18.77
52 Week Low
$0.82
$0.14
52 Week High
$12.50
$9.97

Technical Indicators

Market Signals
Indicator
CVKD
HCTI
Relative Strength Index (RSI) 66.44 47.07
Support Level $0.88 $2.18
Resistance Level $2.23 $3.41
Average True Range (ATR) 0.21 0.65
MACD 0.07 -0.29
Stochastic Oscillator 78.44 4.32

Price Performance

Historical Comparison
CVKD
HCTI

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

About HCTI Healthcare Triangle Inc.

Healthcare Triangle Inc is a healthcare information technology company focused on advancing industry-transforming solutions in the sectors of cloud services, data science, and professional and managed services for the healthcare and life sciences industry. The company reinforces healthcare progress through technology and extensive industry know-how. HTI supports healthcare providers and payors, hospitals, and Pharma Life Sciences organizations in their efforts to improve health outcomes by enabling the adoption of new technologies, data enlightenment, business agility, and accelerated response to immediate business needs and competitive threats. It provides services under three operating segments: Software Services, Managed Services, and Support and Corporate & others.

Share on Social Networks: